Disclaimer

This presentation and the accompanying slides (the “Presentation”), which has been prepared by the Company, has been prepared for information purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securities of the Company, and shall not constitute an offer, solicitation or invitation or recommendation to buy or sell in any jurisdiction in which such offer, solicitation or invitation or recommendation is unlawful. No part, or all, of this Presentation shall form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities of the Company. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration under such act.

Nothing in the foregoing shall constitute and/or deem to constitute an offer or an invitation to an offer, to be made to the Indian public or any section thereof through this document, and this document and its contents should not be construed to be a prospectus in India. This document has not been and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India.

This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form for any purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as “expects” and “anticipates” and words of similar import. Any statement in this Presentation that is not a statement of historical fact is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates or prospects in this Presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the Presentation. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company. The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselves about and observe any such restrictions.
Strides 1.0 delivered value. 

Strides 2.0 is next.
Value creation over time

Strategic progression, Significant value unlocked

1990-2004

Learning
- Emerging market FDF company with trading focus

2004-08

Course Correction
- Business rewired towards scarcity-unconventional markets and domains
- Acquisition of front-end platforms in SE Asia, Australia

2008-13

Value Unlock
- Sale of Ascent Pharma and Agila Specialties
- Over $2b worth of value unlocked
- De-levered balance sheet
- Distributed $650M as special dividend, a corporate record in India

Today

Strides 2.0
- B2C Focus
- Branded generics portfolio
- Presence across major regulated markets and Africa continent
- Highly compliant manufacturing base with key global regulatory approvals
- Efficient R&D infrastructure with global filing capabilities
- Experienced leadership team

Investor Presentation, November 2018
Evolution of Strides 2.0

Growth pivots in place with organic and inorganic strategies

- Re-entered Australia through Arrow. Bolt on acquisitions of Generic Partners "Pharmacy Alliance"
- Acquisition of Universal in Africa to rewire "In Africa For Africa Strategy"
- Sale of Africa generics business and Capping investment in Stelis Biopharma
- Divestment of India branded business
- Proposed merger with Apotex in Australia to become a leading player, Foray into high entry barrier market of South Africa

**STRIDES 1.0 (POST DIVESTMENT)**
- 2015: Merger with Shasun for access to pipeline and supply chain security
- 2015: Setup R&D base from scratch (previous R&D setup was part of divestments)
- 2016: Acquisitions in US and Australia to strengthen product offering
- 2017: JV with Vivimed for its US FDA formulations facility for pipeline and de-risked manufacturing
- 2018: *Demerger of B2B oriented Human API business, to deliver shareholder value through Solara

**STRIDES 2.0 (GEARED FOR VALUE)**
Strongly Positioned Today

**STRONG B2C FOUNDATION**

- **Diversified business model**
- **Supply chain security**
- **Strong R&D Capability**
- **Manufacturing operations with high automation**
- **Experienced management team**
- **Best in class Quality Compliance**

**Scope**
- Well diversified consumer facing business in regulated and Africa continent

**Infrastructure**
- Highly compliant manufacturing base with key global regulatory approvals
- FDF facilities in India, Europe, Africa and Singapore
- Supply chain security through long term supply agreements for API with our strategic partner Solara

**Research**
- Efficient R&D infrastructure
- Global filing capabilities

**Portfolio**
- Capabilities in multiple delivery technologies and dosage formats
- Portfolio across orals, topicals, liquids, creams, ointments, soft gels, tablets and modified release formats

**Management**
- Experienced management team with strategic oversight of a reconstituted Board

**Compliance**
- Strong compliance environment with impeccable regulatory track record
- Technology led complete control on operations, quality and data management

**CAPEX AND INVESTMENT CYCLE NOW COMPLETE, GEARED FOR EXECUTION**
Strides 2.0 strategy is in place. **Focus is on execution.**

- United States
- Australia
- Other Regulated – UK, Europe, South Africa
- Africa
- Institutional Business
Execution in Play
Sharpened focus across all value drivers

Diversified market positioning
Diversified B2C business model with frontend presence across regulated markets and Africa continent

Technology and Compliance
Highly compliant culture led by technology driven quality environment

Experienced Management Team with Board Oversight

Future ready manufacturing base
Highly compliant manufacturing base with key global regulatory approvals

Strong and efficient R&D Capability
Capabilities across key oral solid dosage formats including topicals, liquids, creams and ointments, soft gels, tablets and modified release

Investor Presentation, November 2018
Diversified market positioning
Consumer facing formulation businesses

STRIDES 2.0

Regulated Markets
- Front end presence across Australia, US, UK and South Africa
- Strategic partnerships in other regulated markets
- USFDA approved facilities in India, Europe, upcoming regulated market facility in Singapore*
- Efficient R&D infrastructure
- Reached capacity of 20-25 ANDA filings per annum

Africa Continent
- Front End focus markets of Africa, South East Asia with a portfolio of branded generics
- “In Africa for Africa” strategy with the acquired facility of Universal Corporation, Kenya
- Sales force promoting brands to medical practitioners
- Catering to donor funded programs using the local facility in Africa

*Expected to come on-stream in H2 FY 19

Investor Presentation, November 2018
Differentiated Strategy for Continued Growth

Focused approach for each market

FOOTPRINT ACROSS 100+ REGULATED MARKETS AND AFRICA CONTINENT

UNITED STATES
Own front end with a differentiated portfolio

EUROPEAN UNION
Driven by UK front end and strategic tie ups in rest of Europe

AUSTRALIA
Leadership position in generics and OTC

AFRICA
Own front end in French, West and East Africa with “In Africa, for Africa“ strategy
Recent foray into high entry barrier market

SOUTH AFRICA
Leadership position in generics and OTC

Investor Presentation, November 2018
Growth Markets.

Competitive Positioning.
United States

In growth phase, Anchor market for future

Opportunity
- $467b+ market with patent expiry of brands worth $77.2b in the next 5 years
- Indian generics have 40% of volumes in US market
- Regulatory overhang paving way for fully compliant players
- New GDUFA guidelines accelerating entry of new players and products

Business Today
- Portfolio of 80 filed ANDAs 27 pending approval
- Strong go to market capability through own frontend
- Key frontend products have captured leadership position:
  Ergocalciferol 56%, Ranitidine 36%, Acarbose 37%, Dutasteride 30%, Buspirone 39%, Methoxsalen 57%
- This portfolio witnessed a single digit price erosion

Strategy
- Focus on niche, low competition, high technology barrier products built around modified release, soft gel capsules, topicals
- Target of 20-25 filings every year, to benefit from new GDUFA regulations
- Exit partnership business, no new partnership contracts being entered into

Growth Enablers
- Strong and efficient R&D capability, Filings momentum to continue with 20-25 ANDA filings per year
- Future ready mirrored facilities with capabilities across dosage forms
- Leveraging front end capabilities to go direct to market
Strong and Efficient R&D Capability

Calibrated to Version 2.0

Filings momentum to continue with 20-25 ANDA filings per year

Organization
Modelled on Full Time Equivalence (FTE) structure for improved efficiency and increased scientific collaboration

Differentiated Portfolio
Focus on difficult-to-develop and differentiated products

Dosage Capabilities
Orals, topicals - Liquids, creams and ointments, soft gels (Rx), sachets, tablets, and modified release dosage formats

Paperless
Capable of developing and filing products for all regulated markets

Proficient Regulatory Network
Oracle Agile based Product Lifecycle Management systems from conception to filing
In a sweet spot under new GDUFA guidelines

Filing and approvals seeing strong momentum

- Longer approval cycles, backlog of ANDAs pending for approval

Pre-GDUFA

Average approval cycles >60 months (Pre 2012)

- FDA’s Commitment to reduce timeline to 10 months from 60 months by Oct 2017
  - Split into 5 yearly cohorts having different timelines ranging from 10-40 months
  - For ANDAs in year 5 cohort, review within 10 months after submission

GDUFA-I

Average Approval cycle of 10-40 months (Oct 12-Oct 17)

- Most pending approvals under Cohort 4&5
- Subdued filings as R&D was re-established after Agila

GDUFA II

- All ANDAs fall under single cohort
- Faster review between 8 and 10 months with objective to approve ANDA in first cycle

- Expected approvals in 8-10 months

GISCAL YEAR


PRE-GDUFA

Pending
Total Filings

30**

Legacy filings (FDA backlog)

Fiscal Year

2013 Subdued filings as R&D was re-established after Agila

Legacy filings (FDA backlog)

* Includes 1 ANDA filed in fiscal year 2013, ** includes 4 ANDA filed in fiscal year 13
**Exciting growth pipeline nearing approval**

**Bigger products faster to market**

<table>
<thead>
<tr>
<th>Pending Approvals</th>
<th>Approval timeline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Majority approvals pending under GDUFA 1 Cohort 5 and GDUFA II</strong></td>
<td></td>
</tr>
<tr>
<td>PRE-GDUFA (LEGACY)</td>
<td>1</td>
</tr>
<tr>
<td>GDUFA I (COHORT 1-3)</td>
<td>2</td>
</tr>
<tr>
<td>GDUFA I (COHORT 4)</td>
<td>2</td>
</tr>
<tr>
<td>GDUFA I (COHORT 5)</td>
<td>6</td>
</tr>
<tr>
<td>GDUFA II</td>
<td>11</td>
</tr>
</tbody>
</table>

![Robust Visibility on the pipeline](image)

- 27 ANDA’s pending approval with the USFDA filed mostly in cohort 5 of GDUFA 1 and under GDUFA II
- Continued niche portfolio strategy with $9.5 b addressable opportunity as per IMS
  - 9 Para IV opportunities
  - 4 approved Para IV’s of Fingolimod (US$ 2.2 b), Roflumilast (US$ 210 M), Cinacalcet (US$ 1.8 b), Milnacipran (US$ 140 Mn)
  - 5 Para IV ANDA’s pending approval
- Receives acceptance from USFDA for 2 key ANDAs under newly introduced Competitive Generic Therapy. Combined market for the two products is US$ 550 Mn and these products could be eligible for a potential 180-day exclusivity
- Strong approval momentum to continue with 9 approvals already received in FY 19
- Ramp up filings to 20-25 per year across specialized dosage formats to benefit from FDA’s focus on quicker approval to low competition drugs
- Capped R&D investments at $20 million per year

**Investor Presentation, November 2018**
Future ready manufacturing base

Highly compliant manufacturing base, capacity mapped

BY MANUFACTURING CAPABILITY

- FDF
- Emerging Market Facility

*JV with Vivimed Private Limited.

Investor Presentation, November 2018
Structured approach of product development & lifecycle management embedded with QBD

Emphasis on skill & competency development of employees

Integrated QMS with increased effectiveness

- OPEN COMMUNICATION
- EMPLOYEE EMPOWERMENT
- TECHNOLOGY LED
- KNOWLEDGE DRIVEN
- AWARENESS FOCUS

Proprietary Interactive Mobile App for awareness & feedback

Quality & compliance-Culture build through Integrity, Collaboration & Efficiency Framework

Investor Presentation, November 2018
Australia Generic Market Landscape

A market with high entry barrier

Current Generic Market Shares 2017
Source: Sinapse data analytics

- Arrow, 24%
- Apotex, 30%
- Mylan, 24%
- Sandoz, 18%
- Ranbaxy & Others, 4%

Attractive pharmaceutical and OTC market

- Generic market size at $1.8b, market consolidated due to high cost of operation and high competitive barriers
- Generic substitution currently at ~75%, significantly lower than other developed markets
- Presence of 4 major generic companies – Apotex, Arrow, Mylan and Sandoz, all have their market positioning and customer base
- Total range across 4 major companies is between 160 - 220 molecules
- Top 3 wholesaler Sigma, Symbion and API command 95% market share and are mapped to a generic supplier as a preferred partner
- Attractive OTC market currently pegged at $ 3.7b
- Fragmented base of 5,500 retail pharmacies, with no pharmacist owning more than 5 pharmacies
- Tie up with buying groups and banner groups a critical success factor

*Arrow acquired Amneal’s Australian business in 2017
Australia
Settled Strategy, poised for leadership

Opportunity
- Market to stay consolidated with high entry barriers for new entrants
- Pharmacy ownership to stay independent by law, opportunity to consolidate under buying and banner groups
- Changes in PBS reimbursements regulations driving expansion of generics market

Business Today
- Ranks #2 by volume and #3 by revenues
- Strong OTC portfolio through Chemist’s Own OTC franchise
- Own nation wide sales force driving distribution and loyalty in generics and proprietary Chemist’s own portfolio
- First-line pharmacy coverage of 1,500+ stores

Strategy
- To become market leader in Australia
- Expansion of product portfolio through in-house development and in-licensing opportunities
- Enhance pharmacy coverage to 2000+ first line pharmacies with high loyalty across footprints
- Backward integration momentum to continue and supplies from India to contribute to further COGS savings

Growth Enablers
- Signed a 10 year exclusive distribution agreement with Sigma, a major distributor
- New product introduction (Rx and OTC) including drugs going off patent
- Continue to enhance pharmacy footprint
- Increase in loyalty and substitution through Pharmacy Alliance, across the pharmacy footprint
Strides & Apotex agree to merge in Australia

Getting to pole position in Australia

Strategic rationale
- The combination will enable Strides, through the merged business, to become the number 1 Australian generic pharmaceutical company by both volume and revenue
- The merged business to have the largest portfolio of owned product IP for the Australian market

Management team
- Dennis Bastas, Arrow, will lead the merged business as Executive Chairman, Roger Millichamp, Apotex, as CEO and Andrew Burgess, Arrow, as CFO
- The team brings together Australia’s most experienced management team with in-depth knowledge of the Australian generics market

Transaction structure
- The proposed structure will be arrived through a share swap
- Strides to have controlling interest in the merged entity
- The detailed corporate structure will be announced on closing
- Australian Competition and Consumer Commission (ACCC) on Sep 20, 2018 decided not to oppose the merger
- The transaction is subject to customary closing conditions and statutory approvals, including approval from the Australian Foreign Investment Review Board

Key Highlights
- Arrow and Apotex will continue to enjoy preferred partner relationship with Sigma and Symbion respectively
- The merged entity will service ~3200 first line pharmacy accounts taken together. Arrow currently has 1400 + front line pharmacy accounts including Amcal, Guardian, Pharmacy Alliance, DDS & PharmaSave Stores. Apotex presently has 1800+ front line pharmacy accounts including Terry White, Chemmart, Blooms & Pharmacy Choice stores.
- Potential synergies will accrue through higher volumes and improved COGS
- Cross-pollination of the portfolio will help fill gaps in Arrow and Apotex portfolio’s immediately
- Merged business will mainly benefit from Strides’ and Apotex’s manufacturing facilities
- The proposed merger to be EPS accretive from Year 1 through synergies
Other Regulated Markets

Portfolio and geographical expansion to be the key growth drivers

**Opportunity**
- The European pharmaceutical market is likely to grow to $230b by 2022
- Growth expected on innovations in medicinal drugs across therapy areas including multiple sclerosis, chronic heart failure, rheumatoid arthritis and Alzheimer’s.
- Recent foray into South Africa, a large private market for Anti–retroviral’s

**Business Today**
- Diversified portfolio including Rx soft gelatin capsules, sachets and oral solids in wide ranging therapies
- Established UK Front end supplying generics to hospitals approved by NHS
- Registration Capability for regulatory markets of Europe including UK

**Strategy**
- Focus on portfolio maximization through global regulated market portfolio
- Increasing coverage by expanding front end presence in UK
- Strategic partnerships to carry own IP generics to rest of Europe

**Growth Enablers**
- Leveraging existing portfolio of US and Australia
- More listing at wholesalers in the UK
- Expansion of product offering through strategic tie ups in the rest of Europe and other new geographies
- Manufacturing facilities with key EU approvals including MHRA
- Leverage Trinity’s established distribution channel in South Africa
"In Africa for Africa" theme with focus on Branded Generics

**Opportunity**
- Macro tailwinds with increased urbanization, purchasing power and healthcare infrastructure
- Increasing incidences of chronic lifestyle diseases
- Market expected to reach $44b by 2020
- Regulatory trend towards global standards such as WHO pre-qualification for manufacturing

**Strategy**
- To become a Sub-Saharan Africa branded generic player with leadership position in key markets and therapies
- Focus on lifestyle chronic therapies- driven by brands

**Business Today**
- Footprint in 40+ countries across Sub-Saharan Africa, Local medical field force with coverage of 30,000 doctors
- Industry leading secondary sales growth
- 750 product registrations with a pipeline of 500 product registrations
- Strong brand equity being a local player with the doctors and community

**Growth Enablers**
- Manufacturing consolidation under the WHO approved facility in Kenya and dedicated EM plant in India
- Well established player in West Africa, expanding footprint in East Africa to strengthen the branded generic platform
- Focus on introduction of new products and better penetration of high growth markets

Investor Presentation, November 2018
Institutional Business

Focus on new treatment regimens

**Opportunity**
- Market opportunity of $2.5b in terms of procurement
- Concentrated market with 5-6 key players holding majority of the business
- New treatment regimen attracting donor funding

**Business Today**
- Approved supplier to institutionally funded aid projects and global procurement agencies like UNITAID, PEPFAR, CHAI and Global Fund
- Strong Portfolio of products in HIV, anti-malaria, and Hep-C
- Filed dossiers with product registrations across Emerging markets

**Strategy**
- R&D focus on developing next generation products as per donor agency guidelines
- Leverage strong visibility with innovator organization to be amongst the first wave of launches in select emerging markets

**Growth Enablers**
- Capitalizing on WHO Approved manufacturing facility in Kenya for global donor agencies and local government tenders
- Robust delivery track record with superior supply chain execution
- Leg up in ARV growth through the introduction of next-generation combinations drugs inline with evolving treatment regimens, product already in R&D pipeline for development
- Increased collaboration for voluntary licensing

---

Investor Presentation, November 2018
Robust Planning.
Sustainable growth.
Strides 2.0 - Continued Growth & Value Creation

Strong Business Foundation

- Highly compliant manufacturing base
- Strong and efficient R&D infrastructure
- Capabilities in multiple delivery technologies and dosage formats
- Front-end presence in regulated and Africa continent

Steady Growth through Execution

- Expanding portfolio range with addition of differentiated and limited competition products
- Leveraging a strong “Go To Market” capability to expand distribution network across Australia, US and Europe
- Building portfolio of strong brands in Africa

Steady returns to the stakeholders

- Focus on generating operating leverage
- Identifying newer growth avenues to deliver sustainable growth
- Enhancing shareholders return with an improved ROE profile

Experienced Management team

Foundation of Quality, compliance & governance

Transparent and open culture
## Consolidated Financials

### Key Financial Highlights FY 18

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>Figure</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td></td>
<td>INR 28,576 Mn</td>
</tr>
<tr>
<td><strong>Net Worth</strong></td>
<td></td>
<td>INR 26,092 Mn</td>
</tr>
<tr>
<td><strong>EBITDA and Margin</strong></td>
<td></td>
<td>INR 4,369 Mn (15%)</td>
</tr>
<tr>
<td><strong>Net Debt(^1)</strong></td>
<td></td>
<td>INR 17,063 Mn</td>
</tr>
<tr>
<td><strong>Adjusted PAT(^2)</strong></td>
<td></td>
<td>INR 1,304 Mn</td>
</tr>
<tr>
<td><strong>Net Debt / EBITDA</strong></td>
<td></td>
<td>3.9x</td>
</tr>
<tr>
<td><strong>Adjusted EPS</strong></td>
<td></td>
<td>INR 14.6 / Share</td>
</tr>
<tr>
<td><strong>Dividend Per Share</strong></td>
<td></td>
<td>INR 2.0 / Share</td>
</tr>
</tbody>
</table>

1. Adjusted debt includes cash receivable of ₹1,310M on account of divestment of SCPL and ₹662M for loans advanced to partners.
2. Adjusted PAT- For FY18 - Adj for Stelis share of loss ₹144M, SCPL goodwill impairment ₹ 14M, restructuring expense ₹ 196M, CHC loss 446M.
Experienced Board and Management team

High engagement on areas of strategic focus

Arun Kumar
Founder, Group CEO and MD

Deepak Vaidya
Non-Executive Chairman

Sangita Reddy
Independent Director

Bharat Shah
Independent Director

S. Sridhar
Independent Director

Homi R Khusrokhan
Independent Director

Badree Komandur
Executive Director and CFO

Shashank Sinha
CEO - International Business

Ramaraju PVS
Chief Operating Officer

Umesh Kale
Chief Quality Officer

Lakshmi Narayanan
Chief Information and Technology officer

Investor Presentation, November 2018
Thank You